Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




CRISPR-Powered Method for Non-Invasive Blood Tests to Help Diagnose Early Stage Cancer

By LabMedica International staff writers
Posted on 02 Jun 2023
Print article
Image: A portable smartphone-based POC device for use with EXTRA-CRISPR method for cancer diagnostics (Photo courtesy of UF Health)
Image: A portable smartphone-based POC device for use with EXTRA-CRISPR method for cancer diagnostics (Photo courtesy of UF Health)

MicroRNAs, tiny RNA molecules that regulate gene expression, have been identified as potential cancer biomarkers in human fluids like blood. Extracellular vesicles, tiny particles actively discharged by cells, transfer biomolecules between cells, influencing cell functions and diseases. Tumor cells tend to release these vesicles with disease-associated microRNAs more aggressively, making them a promising source for discovering new cancer markers. However, their clinical application has been constrained due to their complexity and the absence of a tool sensitive enough for their detection. Although CRISPR technology, a potent gene-editing tool, has been increasingly recognized as a potential platform for developing new disease diagnostics, earlier CRISPR tests were not as sensitive as the gold standard RT-qPCR and involved multistep reactions with manual handling. Now, a new approach, called “EXTRA-CRISPR,” could represent a game-changing method in the microRNA testing field.

A team of researchers from University of Florida (Gainesville, FL, USA) has developed an innovative CRISPR-based strategy for non-invasive blood tests that could assist clinicians in diagnosing cancer at earlier stages. The new method, which detects microRNAs in extracellular vesicles, is as effective as the widely used RT-qPCR assays for cancer diagnosis and can be combined with a simple portable device for point-of-care clinical testing. With the aim of streamlining the complete workflow into a 'one pot' setup, the researchers created a quick, sensitive method to detect microRNAs that is simpler and reduces the risk of cross-contamination. The term 'one pot' signifies that all necessary chemical agents, except for the sample, are housed in a single test tube, and only the microRNA sample needs to be added for a reaction to carry out the analysis.

The researchers decided to tailor this technology for pancreatic cancer due to the high mortality rate associated with the disease. They demonstrated that the novel one-pot assay could be adapted for two detection methods commonly used for point-of-care testing. Using readily available components, including a blue LED illuminator, a plastic filter, and a coffee mug warmer, they first prototyped a portable smartphone-based device. These components were assembled on a 3D-printed body part, and a smartphone was attached to capture fluorescence images of the test vials post-reaction to measure the target markers. Alongside the fluorescence detector, they paired the EXTRA-CRISPR assay with a commercially available lateral-flow test strip to create an instrument-free point-of-care device. Both point-of-care methods were tested for pancreatic cancer detection, and they delivered diagnostic results consistent with those obtained with a benchtop PCR machine. A patent application has been filed by the researchers based on this work to make the one-pot CRISPR assay and the point-of-care technology widely accessible for basic research and clinical application.

“Our method is very promising for diagnosis of cancer, such as pancreatic cancer, when combined with robust microRNA biomarkers and for point-of-care testing,” said He Yan, Ph.D., a postdoctoral researcher who was part of the team. “In the future, this method can be coupled with a very simple, low-cost portable device to make pancreatic cancer detection simpler but still reliable.”

Related Links:
University of Florida 

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
cTnI/CK-MB/Myo Test
Finecare cTnI/CK-MB/Myo Rapid Quantitative Test
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.